Biomarkers of acute kidney injury
Biomarkers of acute kidney injury
复制标题
DOI：
10.1053/j.ackd.2008.04.003
复制
发表时间：
2008-07-01
影响因子：
2.9
通讯作者：
Edelstein, Charles L.
中科院分区：
文献类型：
--
作者：
Edelstein, Charles L.
急性肾损伤（阿基）的诊断通常基于血尿素氮的测量。(BUN)和血清肌酸酐。BUN和血清肌酐对于阿基的诊断不是非常敏感或特异，因为它们受到许多独立于肾损伤或肾功能的肾脏和非肾脏因素的影响。在临床前研究中发现了主要由受损肾脏产生的阿基生物标志物。在阿基患者的临床研究中，这些生物标志物中的一些（例如，白细胞介素-18、中性粒细胞明胶酶相关脂质运载蛋白和肾损伤分子-1）已显示在血清肌酐升高之前在尿液中升高。阿基的这些早期生物标志物正在不同类型的阿基和更大规模的临床研究中进行测试。阿基的生物标志物也可以预测长期肾脏结局和死亡率。(C)2008年，美国国家肾脏基金会（National Kidney Foundation，Inc.）All rights reserved.
The diagnosis of acute kidney injury (AKI) is usually based on measurements of blood urea nitrogen. (BUN) and serum creatinine. BUN and serum creatinine are not very sensitive or specific for the diagnosis of AKI because they are affected by many renal and nonrenal factors that are independent of kidney injury or kidney function. Biomarkers of AKI that are made predominantly by the injured kidney have been discovered in preclinical studies. In clinical studies of patients with AKI, some of these biomarkers (eg, interleukin-18, neutrophil gelatinase-associated lipocalin, and kidney injury molecule-1) have been shown to increase in the urine before the increase in serum creatinine. These early biomarkers of AKI are being tested in different types of AKI and in larger clinical studies. Biomarkers of AKI may also predict long-term kidney outcomes and mortality. (C) 2008 by the National Kidney Foundation, Inc. All rights reserved.